Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lynparza Poised For Growth With Broad Ovarian Cancer Approval

Executive Summary

AstraZeneca's Lynparza now has the broadest US label of all PARP inhibitors for ovarian cancer, as well as competitive dosing, posing a threat to Tesaro's reigning Zejula.

Advertisement

Related Content

How Ovarian Cancer Maintenance Therapies Stack Up On Costs And Value
QUADRA Supports Broader Use For Tesaro's PARP Inhibitor Zejula
Buoyed By US Tax Reform, Merck Plans $12bn In Capital Investments
PharmaMar Endures Second Recent Setback With Phase III Ovarian Cancer Failure
The PARP Combo Race Is On: Clovis And Bristol Partner On Rubraca
A Whopper Of A Deal: AZ Hands Half Of Lynparza To Merck
Clovis's Rubraca Leapfrogs Rivals In Ovarian Cancer As ARIEL3 Hits
AstraZeneca's OlympiAD Trial Kick-Starts PARP In Breast Cancer
Broad Label Gives Tesaro's Niraparib A Head Start In Ovarian Cancer
AstraZeneca Mulls Broad Ovarian Cancer Maintenance Approval For Lynparza

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC099335

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel